alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 520.88b Amoxicillin trihydrate for oral suspension. ( a ) *Specifications.* When reconstituted, each milliliter contains amoxicillin trihydrate equivalent to 50 milligrams (mg) amoxicillin.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter. ( 1 ) *Conditions of use* — ( i ) *Dogs* — ( A ) *Amount.* Administer orally 5 mg per pound (/lb) of body weight, twice a day for 5 to 7 days.
( B ) *Indications for use.* Treatment of infections caused by susceptible strains of organisms as follows: respiratory tract (tonsillitis, tracheobronchitis) caused by *Staphylococcus aureus, Streptococcus* spp., *Escherichia coli,* and *Proteus mirabilis;* genitourinary tract (cystitis) caused by *S. aureus, Streptococcus* spp., *E. coli,* and *P. mirabilis;* gastrointestinal tract (bacterial gastroenteritis) caused by *S. aureus, Streptococcus* spp., *E. coli,* and *P. mirabilis;* bacterial dermatitis caused by *S. aureus, Streptococcus* spp., and *P. mirabilis;* and soft tissues (abscesses, lacerations, and wounds) caused by *S. aureus, Streptococcus* spp., *E. coli,* and *P. mirabilis.*
( C ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( ii ) *Cats* — ( A ) *Amount.* Administer orally 5 to 10 mg/lb of body weight, once daily for 5 to 7 days.
( B ) *Indications for use.* Treatment of infections caused by susceptible strains of organisms as follows: upper respiratory tract due to *Staphylococcus* spp., *Streptococcus* spp., *Haemophilus* spp., *E. coli, Pasteurella* spp., and *P. mirabilis;* genitourinary tract (cystitis) due to *S. aureus, Streptococcus* spp., *E. coli, P. mirabilis,* and *Corynebacterium* spp.; gastrointestinal tract due to *E. coli, Proteus* spp., *Staphylococcus* spp., and *Streptococcus* spp.; skin and soft tissue (abscesses, lacerations, and wounds) due to *Staphylococcus* spp., *Streptococcus* spp., *E. coli,* and *Pasteurella multocida.*
( C ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) [Reserved]
( c ) *Sponsors.* See Nos. 000856 and 051311 in § 510.600(c) of this chapter. ( 1 ) Conditions of use. Dogs — ( i ) *Amount.* Administer orally 5 mg/lb of body weight, twice a day for 5 to 7 days.
( ii ) *Indications for use.* Treatment of bacterial dermatitis due to *S. aureus, Streptococcus* spp., *Staphylococcus* spp., and *E. coli,* and soft tissue infections (abscesses, wounds, lacerations) due to *S. aureus, Streptococcus* spp., *E. coli, P. mirabilis* and *Staphylococcus* spp.
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) [Reserved]
[57 FR 37319, Aug. 18, 1992; 57 FR 42623, Sept. 15, 1992, as amended at 60 FR 55658, Nov. 2, 1995; 62 FR 13302, Mar. 20, 1997; 67 FR 67521, Nov. 6, 2002; 68 FR 54658, Sept. 18, 2003; 68 FR 55824, Sept. 29, 2003; 79 FR 28816, May 20, 2014; 81 FR 17607, Mar. 30, 2016]
<PAGE>


                                                                      EXHIBIT 32



                                ORTHOMETRIX, INC.
                          FORM 10-KSB DECEMBER 31, 2003


                            CERTIFICATION PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         In connection with the Annual Report of Orthometrix, Inc., (the
"Company"), on Form 10-KSB for the year ended December 31, 2003, as filed with
the Securities and Exchange Commission on the date hereof (the "Report"), the
undersigned, in the capacities and on the date indicated below, hereby certifies
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that to his knowledge: (1) the Report fully complies
with the requirements of Section 13(a) or 15(d) of the Securities and Exchange
Act of 1934; and (2) the information contained in the Report fairly presents, in
all material respects, the financial condition and results of operations of the
Company.



Date:  March 31, 2004                                /s/ Reynald Bonmati
                                                     -------------------
                                                     Reynald Bonmati
                                                     Chief Executive Officer



Date:  March 31, 2004
                                                     /s/ Neil H. Koenig
                                                     ------------------
                                                     Neil H. Koenig
                                                     Chief Financial Officer
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from 
Riverside Park Associates Limited Partnership 1998 Third Quarter 10-QSB 
and is qualified in its entirety by reference to such 10-QSB filing.
</LEGEND>
<CIK> 0000813812
<NAME> RIVERSIDE PARK ASSOCIATES LIMITED PARTNERSHIP
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                    9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               SEP-30-1998   
<CASH>                                           2,121
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0<F1>
<PP&E>                                          74,195
<DEPRECIATION>                                  33,690   
<TOTAL-ASSETS>                                  44,597   
<CURRENT-LIABILITIES>                                0<F1>
<BONDS>                                         45,685     
<PREFERRED-MANDATORY>                                0     
<PREFERRED>                                          0  
<COMMON>                                             0
<OTHER-SE>                                     (2,197)    
<TOTAL-LIABILITY-AND-EQUITY>                    44,597    
<SALES>                                              0
<TOTAL-REVENUES>                                 8,389    
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                 9,170    
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               3,202    
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     (781)     
<EPS-PRIMARY>                                  (1,339)<F2>
<EPS-DILUTED>                                        0
<FN>
<F1>Registrant has an unclassified balance sheet.
<F2>Multiplier is 1.
</FN>
        



</TABLE>
Fourth Court of Appeals

San Antonio, Texas

September 15, 2017

No. 04-17-00308-CR

Gerald WASHINGTON,

Appellant

v.

The STATE of Texas,

Appellee

From the 144th Judicial District Court, Bexar County, Texas

Trial Court No. 2016CR1095

Honorable Lorina I. Rummel, Judge Presiding

O R D E R

Ms. Roxanne Pena is one of the reporters responsible for preparing, certifying, and filing 

the reporter’s record in this appeal. Ms. Pena’s record was originally due on July 10, 2017. On 

July 18, 2017, the Clerk’s Office notified Ms. Pena that the reporter’s record was late. Ms. Pena 

was instructed to file a Notification of Late Record explaining the delay within ten days, or to 

file the reporter’s record by August 17, 2017. Neither a response nor the record has been filed in 

this court.

It is therefore ORDERED that Ms. Pena file the reporter’s record in this court no later 

than September 25, 2017. If the record is not received by that date, an order will be issued 

directing Ms. Pena to appear before this court to show cause why she should not be held in 

contempt for failing to file the record. The clerk of this court shall cause a copy of this order to 

be served on Ms. Pena by certified mail, return receipt requested, and by United States mail. 

And, because the trial and appellate courts are jointly responsible for ensuring that the appellate 

record is timely filed, the clerk of this court shall also cause a copy of this order to be served 

upon the trial court. See TEX. R. APP. P. 35.3(c).

_________________________________

Sandee Bryan Marion, Chief Justice
IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said 

court on this 15th day of September, 2017.

___________________________________

Keith E. Hottle

Clerk of Court
# C_2014329EN.01001001.xml

| 22.9.2014 | EN | Official Journal of the European Union | C 329/10 |
| --- | --- | --- | --- |

22.9.2014

EN

Official Journal of the European Union

C 329/10

---

Action brought on 28 July 2014 — European Parliament v Council of the European Union

(Case C-363/14)

2014/C 329/12

Language of the case: French

Parties

Parties

Applicant: European Parliament (represented by: F. Drexler, A. Caiola, M. Pencheva, acting as Agents)

Applicant:

Defendant: Council of the European Union

Defendant:

Form of order sought

Form of order sought

| — | Annul Council Implementing Decision 2014/269/EU of 6 May 2014 amending Decision 2009/935/JHA as regards the list of third States and organisations with which Europol shall conclude agreements (1) |
| --- | --- |

—

Annul Council Implementing Decision 2014/269/EU of 6 May 2014 amending Decision 2009/935/JHA as regards the list of third States and organisations with which Europol shall conclude agreements (1)

1

| — | order the defendant to pay all the costs. |
| --- | --- |

—

order the defendant to pay all the costs.

Pleas in law and main arguments

Pleas in law and main arguments

In support of its action, the European Parliament raises three pleas in law.

Firstly, the European Parliament contests the use by the Council of an incorrect decision-making procedure for the adoption of Decision 2014/269/EU. The Parliament deduces therefrom that the Council has committed not only a breach of the Treaties but also a breach of essential procedural requirements.

Secondly, the European Parliament complains of the Council’s use either of a legal basis repealed by the entry into force of the Treaty of Lisbon or of a secondary legal basis, which is unlawful pursuant to the case-law of the Court of Justice.

Lastly, in the view of the Parliament, the list of third States and organisations with which Europol is to conclude agreements is a legislative matter. It should be considered by the EU legislature, since it is an essential element of a regulated area. In consequence, the legal basis and procedure used by the Council are legally incorrect.

---

(1)  OJ 2014 L 138, p. 104.

1

---
#### GRAND RAPIDS & INDIANA RAILWAY CO. *v.*KALAMAZOO CIRCUIT JUDGE.

Venue — Change—Actions in Which Authorized — Condemnation Proceedings.

Act No. 161, Pub. Acts 1907, authorizing a change of venue in any “cause” pending, was not intended to extend the jurisdiction previously existing, and hence did not authorize a change of venue in proceedings to condemn land for a railroad right of way.

Mandamus by the Grand Rapids & Indiana Railway Company to compel John W. Adams, circuit judge of Kalamazoo county, to vacate an order denying a change of venue.

Submitted September 8,1908.

(Calendar No. 23,1141⁄2.)

Writ denied November 2, 1908.

*James H. Campbell,*for relator.

*A If red J. Mills,*for respondent:

Blair, J.

This is an application for an order requiring respondent to show cause why he should not vacate *494his order denying a petition for change of venue in the condemnation proceedings reported as Chicago, *etc., R. Co.*v. *Grand Rapids, etc., R. Co.,*153 Mich. 686. The respondent refused to grant a change of venue upon the sole ground that he had no jurisdiction or power to grant a change of venue in condemnation proceedings, regardless of the showing made. The trial judge was clearly right in his holding, unless the amendment of 1907 (Act No. 161, Pub. Acts 1907) has effected a change in the law as to such proceedings. *Michigan, etc., R. Co.*v. *Monroe Circuit Judge,*144 Mich. 44.

Act No. 309, Pub. Acts 1905, provided:

> “Each of said courts may change the venue of any criminal action pending therein, upon good cause shown, and shall change the venue of *any civil action*pending therein, upon the application,” etc.

The amendment of 1907 provides:

> “ Each of the said courts, upon good cause shown, may change the venue in *any cause*pending therein,” etc.

We find no reasonable ground for determining that the legislature intended, by the use of the word “cause,” instead of the word “ action,” to extend the jurisdiction of the courts in civil cases. The words “any cause” were intended to embrace and have the same meaning as the words ‘ ‘ any criminal action ” and ‘ ‘ any civil action;” both classes of actions being brought under the same rule as to the character of the showing to be made. Manifestly the proviso was not intended to enlarge the jurisdiction, since it merely continued in force “any and all suits, proceedings, causes, or actions ” pending under the act of 1905, which this court had held did not apply in condemnation proceedings.

Application denied, with costs.

Montgomery, Ostrander, Hooker, and Moore, JJ., concurred.
§ 524.1484h Neomycin, penicillin, polymyxin B, and hydrocortisone suspension. ( a ) *Specifications.* Each milliliter of suspension contains 25 milligrams of neomycin sulfate equivalent to 17.5 milligrams of neomycin, 10,000 international units of penicillin G procaine, 5,000 international units of polymyxin B sulfate, 2 milligrams of hydrocortisone acetate, and 1.25 milligrams of hydrocortisone sodium succinate.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Rub a small amount into the affected area 1 to 3 times a day. After definite improvement, apply once daily or every other day.
( 2 ) *Indications for use.* For the treatment of summer eczema, atopic dermatitis, interdigital eczema, and otitis externa caused by bacteria susceptible to neomycin, penicillin, and polymyxin B.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( d ) *Conditions of use—dogs* — ( 1 ) *Amount.* Rub a small amount into the involved area 1 to 3 times a day. After definite improvement, it may be applied once a day or every other day.
( 2 ) *Indications for use.* Treatment of summer eczema, atopic dermatitis, interdigital eczema, and otitis externa caused by bacteria susceptible to neomycin, penicillin, and polymyxin B.
( 3 ) *Limitations.* For use in dogs only. Shake drug thoroughly and clean lesion before using. If redness, irritation, or swelling persists or increases, discontinue use and reevaluate diagnosis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[59 FR 5105, Feb. 3, 1994, as amended at 79 FR 10971, Feb. 27, 2014]
EXHIBIT 32.2
                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                    AS ADOPTED PURSUANT TO SECTION 906 OF THE
                           SARBANES-OXLEY ACT OF 2002

In connection  with the  quarterly  report of Avitar,  Inc.  (the  "Company") on
Form10-QSB/A  for the period ending March 31, 2005 as filed with the  Securities
and Exchange Commission on the date hereof (the "Report"), I, Jay C. Leatherman,
Jr.,  Chief  Financial  Officer of the  Company  certify,  pursuant to 18 U.S.C.
Section 1350, as adopted  pursuant to Section 906 of the  Sarbanes-Oxley  Act of
2002, to my knowledge, that:

     (1) The Report  fully  complies  with the  requirements  of  Section  13(a)
or15(d) of the Securities Exchange Act of 1934; and

     (2)  The  information  contained  in the  Report  fairly  presents,  in all
material  respects,  the  financial  condition  and results of operations of the
Company.

Date: February 10, 2006

                                           /s/ Jay C. Leatherman, Jr.
                                           -------------------------
                                           Jay C. Leatherman, Jr.
                                           Chief Financial Officer
                                           (Principal Financial
                                           and Accounting Officer), Secretary
# L_2018317EN.01002101.xml

| 14.12.2018 | EN | Official Journal of the European Union | L 317/21 |
| --- | --- | --- | --- |

14.12.2018

EN

Official Journal of the European Union

L 317/21

---

COMMISSION IMPLEMENTING REGULATION (EU) 2018/1982

of 13 December 2018

on the minimum selling price for skimmed milk powder for the 29th partial invitation to tender within the tendering procedure opened by Implementing Regulation (EU) 2016/2080

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EU) No 1308/2013 of the European Parliament and of the Council of 17 December 2013 establishing a common organisation of the markets in agricultural products and repealing Council Regulations (EEC) No 922/72, (EEC) No 234/79, (EC) No 1037/2001 and (EC) No 1234/2007 (1),

Having regard to Commission Implementing Regulation (EU) 2016/1240 of 18 May 2016 laying down rules for the application of Regulation (EU) No 1308/2013 of the European Parliament and of the Council with regard to public intervention and aid for private storage (2), and in particular Article 32 thereof,

Whereas:

| (1) | Commission Implementing Regulation (EU) 2016/2080 (3) has opened the sale of skimmed milk powder by a tendering procedure. |
| --- | --- |

(1)

Commission Implementing Regulation (EU) 2016/2080 (3) has opened the sale of skimmed milk powder by a tendering procedure.

| (2) | In the light of the tenders received for the 29th partial invitation to tender, a minimum selling price should be fixed. |
| --- | --- |

(2)

In the light of the tenders received for the 29th partial invitation to tender, a minimum selling price should be fixed.

| (3) | The measures provided for in this Regulation are in accordance with the opinion of the Committee for the Common Organisation of the Agricultural Markets, |
| --- | --- |

(3)

The measures provided for in this Regulation are in accordance with the opinion of the Committee for the Common Organisation of the Agricultural Markets,

HAS ADOPTED THIS REGULATION:

Article 1

For the 29th partial invitation to tender for the selling of skimmed milk powder within the tendering procedure opened by Implementing Regulation (EU) 2016/2080, in respect of which the period during which tenders were to be submitted ended on 11 December 2018, the minimum selling price shall be 145,10 EUR/100 kg.

Article 2

This Regulation shall enter into force on the day of its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 13 December 2018.

For the Commission,

On behalf of the President,

Jerzy PLEWA

Director-General

Directorate-General for Agriculture and Rural Development

---

(1)  
  OJ L 347, 20.12.2013, p. 671.

1

(2)  
  OJ L 206, 30.7.2016, p. 71.

2

(3)  Commission Implementing Regulation (EU) 2016/2080 of 25 November 2016 opening the sale of skimmed milk powder by a tendering procedure (OJ L 321, 29.11.2016, p. 45).

3

---
COURT OF APPEALS FOR THE

FIRST DISTRICT OF TEXAS AT HOUSTON

ORDER ON MOTION FOR REHEARING

Appellate case name: Ali Yazdchi v. The Cohen Law Firm, a/k/a Gary Cohen

Appellate case number: 01-19-00719-CV

Trial court case number: 2016-82012

Trial court: 11th District Court of Harris County

On August 12, 2021, this appeal was dismissed for lack of jurisdiction because appellant 

is a vexatious litigant subject to prefiling orders and failed to obtain authorization from the local 

administrative judge prior to filing his notice of appeal on September 17, 2019. After the appeal 

was dismissed, appellant requested authorization from the local administrative judge to file the 

appeal. On August 25, 2021—thirteen days after the appeal was dismissed and nearly two years 

after appellant filed his notice of appeal without prior authorization—the local administrative 

judge granted permission to appeal. Appellant has filed a motion for rehearing based upon this 

subsequent grant of permission. The motion for rehearing is denied.

It is so ORDERED.

Judge’s signature: ____/s/ Gordon Goodman________

Acting for the Court

Panel consist of Justices Goodman, Landau and Countiss

Date: ___September 28, 2021_____
[Cite as Parsons v. Ohio Dept. of Transp., 2011-Ohio-5985.]

Court of Claims of Ohio

The Ohio Judicial Center 

65 South Front Street, Third Floor 

Columbus, OH 43215 

614.387.9800 or 1.800.824.8263 

www.cco.state.oh.us

MARK E. PARSONS, Case No. 2008-11290 

 Plaintiff, 

 v. Judge Joseph T. Clark 

OHIO DEPARTMENT OF TRANSPORTATION, 

 Defendant. JUDGMENT ENTRY

{¶1} On September 14, 2011, the magistrate issued a decision recommending 

judgment for defendant. 

{¶2} Civ.R. 53(D)(3)(b)(i) states, in part: “A party may file written objections to a 

magistrate’s decision within fourteen days of the filing of the decision, whether or not the 

court has adopted the decision during that fourteen-day period as permitted by Civ.R. 

53(D)(4)(e)(i).” No objections were filed. 

{¶3} The court determines that there is no error of law or other defect evident on 

the face of the magistrate’s decision. Therefore, the court adopts the magistrate’s 

decision and recommendation as its own, including findings of fact and conclusions of 

law contained therein. Judgment is rendered in favor of defendant. Court costs are 

assessed against plaintiff. The clerk shall serve upon all parties notice of this judgment 

and its date of entry upon the journal. 

 

 _____________________________________ 

 JOSEPH T. CLARK 

 Judge 

cc: 

Christopher P. Conomy 

Assistant Attorney General 

150 East Gay Street, 18th Floor 

Columbus, Ohio 43215-3130 

Mark E. Parsons 

14653 State Route 555 

Cutler, Ohio 45724 
Case No. 2008-11290 - 2 - JUDGMENT ENTRY

 

Filed October 18, 2011 

To S.C. reporter November 18, 2011
§ 251.6 Termination of authorized importation programs. ( a ) Unless an extension is granted under this part, authorization for a SIP automatically terminates after 2 years, or a shorter period of time if a shorter period of time is specified in the authorization for the SIP.
( b ) The authorization period for a SIP begins when the Importer, or its authorized customs broker, files an electronic import entry for consumption for its first shipment of drugs under the SIP.
( c ) Notwithstanding paragraph (a) of this section, authorization for a SIP terminates if the Importer, or its authorized customs broker, does not file an electronic import entry for consumption for a shipment of eligible prescription drugs under the SIP within 1 year of the date that the SIP was authorized.
( d ) FDA will terminate authorization of a SIP upon request from the SIP Sponsor.
( e ) An eligible prescription drug cannot be shipped into the United States under this part, and is subject to refusal of admission into the United States, if the authorization of the SIP has terminated.